[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610725":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":22,"responsibleParty":70,"collaborators":7,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":74,"sex":80,"minAge":81,"maxAge":7,"enrollmentInfo":82,"targetDuration":7,"studyType":85,"phases":7,"briefSummary":86,"conditions":87,"keywords":7,"overallStatus":89,"whyStopped":7,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"The George Institute","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DIAGNOSTIC_TEST","LVOne","LVOne is an in vitro diagnostic rapid lateral flow chromatographic immunoassay kit",[14,19],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Craig Anderson, MD","CONTACT","+61 4039448107","canderson@georgeinstitute.org.au",{"name":20,"role":16,"phone":7,"phoneExt":7,"email":21},"Cheryl Carcel, MD","ccarcel@georgeinsitute.org.au",[23,43,52,61],{"facility":24,"status":7,"city":25,"state":26,"zip":7,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"Liverpool Hospital","Sydney","New South Wales","Australia","AU",{"type":30,"coordinates":31},"Point",[32,33],151.20732,-33.86785,{"lat":33,"lon":32},[36,40],{"name":37,"role":16,"phone":38,"phoneExt":7,"email":39},"Cheryl Carcel","+61 2 8052 4508","ccarcel@georgeinstitute.org.au",{"name":41,"role":42,"phone":7,"phoneExt":7,"email":7},"Dennis Cordato","PRINCIPAL_INVESTIGATOR",{"facility":44,"status":7,"city":25,"state":26,"zip":7,"country":27,"countryCode":28,"cosmosGeoPoint":45,"geoPoint":47,"contacts":48},"Nepean Hospital",{"type":30,"coordinates":46},[32,33],{"lat":33,"lon":32},[49,50],{"name":37,"role":16,"phone":38,"phoneExt":7,"email":39},{"name":51,"role":42,"phone":7,"phoneExt":7,"email":7},"Sameen Haque",{"facility":53,"status":7,"city":25,"state":26,"zip":7,"country":27,"countryCode":28,"cosmosGeoPoint":54,"geoPoint":56,"contacts":57},"New South Wales Ambulance",{"type":30,"coordinates":55},[32,33],{"lat":33,"lon":32},[58,59],{"name":37,"role":16,"phone":38,"phoneExt":7,"email":39},{"name":60,"role":42,"phone":7,"phoneExt":7,"email":7},"David Patterson",{"facility":62,"status":7,"city":25,"state":26,"zip":7,"country":27,"countryCode":28,"cosmosGeoPoint":63,"geoPoint":65,"contacts":66},"Royal North Shore Hospital",{"type":30,"coordinates":64},[32,33],{"lat":33,"lon":32},[67,68],{"name":37,"role":16,"phone":38,"phoneExt":7,"email":39},{"name":69,"role":42,"phone":7,"phoneExt":7,"email":7},"Christopher Partyka",{"type":71,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100610725","interact4-expansion---validation-study-100610725",false,"NCT07231315","INTERACT4 Expansion - Validation Study","INTEnsive Ambulance-delivered Blood Pressure Reduction in Biomarker-identified Hyper-ACute Intracerebral Haemorrhage Trial - Validation Study","INTERACT4 Exp","Inclusion Criteria:\n\n1. Adults (age ≥18 years);\n2. Acute syndrome that is due to presumed acute stroke, defined as FAST (Face, Arm, Speech, Time) scores of ≥2 with an arm motor deficit;\n3. Time ≤3 hours from last seen well;\n4. Systolic BP (SBP) ≥150mmHg.\n\nExclusion Criteria:\n\n1. Participants in coma (no response to tactile\u002Fverbal stimulation); or\u002Fand do not respond to \"P\" or \"U\" on the alert\u002Fverbal\u002Fpainful\u002Funresponsive (APVU) responsiveness scale;\n2. Severe known co-morbid disease (e.g. cancer, chronic airflow disease, severe dementia, severe heart failure, pre-existing disability \\[needing help\\]);\n3. Known history of epilepsy or seizure at onset;\n4. Recent head injury (where there is potential for another type of intracranial haemorrhage or head trauma);\n5. Hypoglycaemia (glucose\\\u003C4.0 mmol\u002FL) as measured in the ambulance.","ALL","18 Years",{"count":83,"type":84},465,"ESTIMATED","OBSERVATIONAL","As an investigator-initiated and conducted, multi-centre, open-label, single-arm prospective observational trial, INTERACT4 Expansion aims to evaluate the diagnostic accuracy of GFAP measured using a point-of-care device, for identifying ICH in participants presenting with acute stroke-like symptoms in the pre-hospital setting compared with imaging-confirmed ICH.",[88],"Intracerebral Hemorrhage","NOT_YET_RECRUITING","2025-11-17",{"date":92,"type":93},"2025-11-19","ACTUAL",{"date":95,"type":84},"2026-02-01",{"date":97,"type":84},"2027-06-01",{"name":5,"class":6},4]